ACLARIS THERAPEUTICS INC

Kolbeck Wilhelm’s August 1 insider trade shows confidence in ACLARIS Therapeutics – buying 36,375 shares amid a 285% YTD rally, reinforcing potential upside for investors.

Insider buying at Aclaris Therapeutics signals strong board confidence in its dermatology pipeline and 2027 revenue boost, offering a rare high‑growth biotech opportunity.

Executive equity grants at Aclaris Therapeutics reveal leadership’s long‑term confidence, signalling potential upside if key clinical milestones and payer deals succeed.

Loerop James’ recent Aclaris Therapeutics buy signals insider confidence amid earnings volatility – what it means for investors.